Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
19 Dementia Trials near St. Louis, MO
Power is an online platform that helps thousands of Dementia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Remternetug for Alzheimer's Disease
Saint Louis, MissouriThe purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug.
Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD).
Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurologic, Psychiatric, Stroke, Substance Use, Others
Must Not Be Taking:Anticoagulants, Immunosuppressives, Chemotherapeutics, Others
280 Participants Needed
Lecanemab for Alzheimer's Disease
Saint Louis, MissouriThis is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cancer, Uncontrolled Hypertension, Others
Must Be Taking:Anti-amyloid Therapy
65 Participants Needed
Gantenerumab for Alzheimer's Disease
Saint Louis, MissouriThe purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurologic Disease, Psychiatric Disease, Stroke, Alcohol Use, Others
Must Not Be Taking:Immunosuppressives, Anticoagulants
280 Participants Needed
Investigational Alzheimer's Drugs for Early Onset Alzheimer's Disease
Saint Louis, MissouriThis trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:18 - 80
Sex:All
197 Participants Needed
Disease-Modifying Drugs for Alzheimer's Disease
Saint Louis, MissouriThe purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Alcohol/drug Dependence, Cardiovascular Disease, Others
Must Not Be Taking:Anticoagulants, Monoclonal Antibodies
490 Participants Needed
Music Therapy and Social Work Telehealth for Healthy Aging
Saint Louis, MissouriThis study investigates the benefits of using telehealth services, specifically a combination of music therapy and social work support, to improve the well-being of older adults. Investigators are focusing on outcomes such as reduced loneliness, improved cognition, and how well older adults with and without dementia perceive the quality of the services received. This research is crucial because as the population ages and conditions like Alzheimer's become more prevalent, effective psychosocial interventions are needed.
The collaborative telehealth approach of the intervention in this study strives to connect older adults to community and health-related services. Older adults experience challenges in accessing services related to transportation, social support, and finances. While the pandemic prompted a rapid shift of healthcare services online, including music therapy and social work, questions remain about the quality of this transition, especially for older adults who may not be familiar with or have the resources for telehealth.
In this pilot study, investigators are studying music therapy and social work support through telehealth to understand how this approach can impact the well-being, cognition, and service quality for older adults, both with and without dementia. Social workers, who focus on improving well-being and addressing various needs, can leverage the therapeutic relationship built by music therapists to better identify and meet service needs. This pilot study builds on a feasibility project, which indicated that this collaborative framework is acceptable, valuable, and of interest to older adults, facilitating remote community connection. Through this research, investigators aim to evaluate the effectiveness of telehealth services for older adults to inform a future larger trial.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65+
Sex:All
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Sensory Impairment, Others
20 Participants Needed
BMS-986446 for Early Alzheimer's Disease
Saint Louis, MissouriThis trial is testing a new medication called BMS-986446 in people with early Alzheimer's disease. The medication is designed to target harmful proteins in the brain to slow down the disease. Researchers are checking if it works well and is safe for patients.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Other Cognitive Conditions, MRI Contraindications, Others
475 Participants Needed
Ramipril for Memory Loss in Glioblastoma Patients
Saint Louis, MissouriThis study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
75 Participants Needed
Risk Disclosure Impact for Alzheimer's Disease
Saint Louis, MissouriThis trial provides participants with a report predicting their future risk of developing Alzheimer’s disease. It targets people without memory or thinking problems in an aging study. The prediction is made using genetic data, brain scans, blood tests, and demographic information.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:65+
Sex:All
450 Participants Needed
Atorvastatin for Preventing Dementia
Saint Louis, MissouriPREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:75+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Dementia, ADL Dependence, Others
Must Not Be Taking:Statins
20000 Participants Needed
JNJ-63733657 for Alzheimer's Disease
Saint Louis, MissouriThis trial is testing a new drug called JNJ-63733657 to see if it can help slow down the worsening of symptoms in patients with Alzheimer's disease. The goal is to see if the drug can help maintain brain function and daily living skills better.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 80
Sex:All
523 Participants Needed
IV VTS-270 for Niemann-Pick Disease
Saint Louis, MissouriNiemann-Pick disease, type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence. NPC results from mutation of either the Niemann-Pick C1 disease (NPC1) (\~95% of cases) or NPC2 genes. NPC is characterized by the endolysosomal storage of unesterified cholesterol and lipids in both the central nervous system and peripheral tissues such as the liver. Individuals with NPC demonstrate progressive central nervous system decline including inability to coordinate balance, gait, extremity and eye movements. Acute liver disease in the newborn/infant period is frequently observed, but subsequently resolves. However, chronic, sub-clinical liver disease persists. Intrathecal 2-Hydroxypropyl-β-Cyclodextrin (HP-β-CD, VTS-270), also known as adrabetadex, has proven effective in reducing the signs and prolonging life in animal models and Phase 1/2a data support efficacy in NPC1 patients. Adrabetadex (VTS-270) also has been shown to be effective in treating liver disease in the NPC1 cat.
This Phase 1/2a, open-label, multiple ascending dose trial will evaluate whether adrabetadex (VTS-270) administered intravenously is effective in treating acute liver disease in NPC1 infants.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:< 6
Sex:All
12 Participants Needed
Donanemab for Early Alzheimer's Disease
Saint Louis, MissouriThis trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85
Sex:All
1736 Participants Needed
AVP-786 for Agitation in Alzheimer's Disease
Creve Coeur, MissouriThis trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 90
Sex:All
1197 Participants Needed
ACI-24.060 for Alzheimer's Disease and Down Syndrome
Saint Louis, MissouriThe purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:35 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Unstable Medical Condition, Drug Abuse, Seizures, Others
Must Be Taking:Acetylcholinesterase Inhibitors, Memantine
140 Participants Needed
Sensory Stimulation for Alzheimer's Disease
Chesterfield, MissouriThis trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Seizure Disorder, Schizophrenia, Heart Disease, Others
Must Be Taking:Acetylcholinesterase Inhibitors
600 Participants Needed
GSK4527226 for Early Alzheimer's Disease
Chesterfield, MissouriThe aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Stroke, CNS Trauma, Alcohol Use, Others
Must Not Be Taking:Antipsychotics, Antidepressants, Opiates, Others
359 Participants Needed
Remternetug for Alzheimer's Disease
Chesterfield, MissouriThis trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85
Sex:All
1667 Participants Needed
AVP-786 for Alzheimer's-related Agitation
O'Fallon, MissouriThis trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 90
Sex:All
241 Participants Needed
Page 1 of 1+
Frequently Asked Questions
How much do Dementia clinical trials in St. Louis, MO pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Dementia clinical trials in St. Louis, MO work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Dementia trials in St. Louis, MO 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in St. Louis, MO for Dementia is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in St. Louis, MO several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Dementia medical study in St. Louis, MO ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Dementia clinical trials in St. Louis, MO ?
Most recently, we added Remternetug for Alzheimer's Disease, Gantenerumab for Alzheimer's Disease and Lecanemab for Alzheimer's Disease to the Power online platform.